OGI - Organigram cut on profitability concerns Novocure downgraded despite positive news and more in today's analyst action

Ongoing profitability a question mark at OrganigramCIBC analyst John Zamparo doesn't see Organigram Holdings (OGI) returning to positive EBIDTA soon, leading him to cut shares to underperformer and reducing his price target to C$3.25 from C$5.He says the COVID-19 pandemic will continue to impact its domestic market share while also impacting higher-margin international sales.Zamparo adds that gross margins will remained depressed through the rest of fiscal 2021 and won't surpass 20% until Q1 fiscal 2022.Wedbush downgrades NovoCure despite positive NSCLC newsWedbush analyst David Nierengarten has downgraded shares of NovoCure (NVCR) to underperform from neutral despite yesterday's news that a data monitoring committee (DMC) recommended a reduced trial duration and patient numbers in its phase 3 LUNAR trial for its Tumor Trial Fields treatment for non-small cell lung cancer.He lowered his priced target from $159 to $154.Nierengarten says that although the development should accelerate trial completion by at least a year, he views

For further details see:

Organigram cut on profitability concerns, Novocure downgraded despite positive news, and more in today's analyst action